Plain-English translation of NCT05948033 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lymphoma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing CD70-targeted CAR-T cells, a new type of treatment that uses your own immune cells to fight lymphoma. Researchers take T cells from your blood, engineer them in the laboratory to recognize and attack lymphoma cells, then put them back into your body. This medication is being tested for patients whose lymphoma has returned or stopped responding to earlier treatments.
Many patients with lymphoma eventually develop cancer that no longer responds to standard treatments, or their cancer comes back after initial therapy. This trial exists because the new treatment targets a different marker on lymphoma cells than existing therapies, offering hope for patients who haven't benefited from other options.
You likely qualify if…
You likely don't qualify if…
You will first undergo a procedure called leukapheresis to collect your T cells from your blood. Next, you will receive chemotherapy drugs (fludarabine and cyclophosphamide) to prepare your body for the engineered cells. Then you will receive an infusion of your newly engineered CD70-targeted CAR-T cells. The trial involves different dose levels — the first patients receive lower doses to test safety, and later patients may receive higher doses. You will need close follow-up monitoring to watch for side effects and to see how well the treatment is working.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China